S&P TSX Capped Composite...

US Dollar vs CAD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

ATOS Atossa Therapeutics Inc

0.73

-0.0076 (-1.03%)

Pre Market

Last Updated: 06:18:30

Delayed by 15 minutes

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From Feb 2025 to Mar 2025

Click Here for more Atossa Therapeutics Charts.

Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From Mar 2024 to Mar 2025

Click Here for more Atossa Therapeutics Charts.

Atossa Therapeutics Inc News

Form 8-K - Current report
Monday 24 February 2025 (2 weeks ago) • Edgar (US Regulatory)

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Friday 7 February 2025 (1 month ago) • Edgar (US Regulatory)

Atossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer Care
Wednesday 5 February 2025 (1 month ago) • GlobeNewswire Inc.

Form 8-K - Current report
Tuesday 4 February 2025 (1 month ago) • Edgar (US Regulatory)

Atossa Therapeutics Responds to PTAB Ruling on U.S. Patent No. 11,572,334 and Announces the Issuance of U.S. Patent No. 12,201,591
Thursday 30 January 2025 (1 month ago) • GlobeNewswire Inc.

Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025
Thursday 23 January 2025 (2 months ago) • GlobeNewswire Inc.

Atossa Therapeutics Applauds U.S. Surgeon General’s Advisory Highlighting Alcohol as a Leading Preventable Cause of Breast Cancer
Monday 6 January 2025 (2 months ago) • GlobeNewswire Inc.

Atossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic with (Z)-endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer Symposium
Thursday 12 December 2024 (3 months ago) • GlobeNewswire Inc.

Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density
Wednesday 11 December 2024 (3 months ago) • GlobeNewswire Inc.

Form 8-K - Current report
Tuesday 10 December 2024 (3 months ago) • Edgar (US Regulatory)

Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium
Tuesday 10 December 2024 (3 months ago) • GlobeNewswire Inc.

Atossa Therapeutics Presents Data from Study Investigating Anti-Cancer Activity of (Z)-Endoxifen-Related Compounds at AACR Special Conference in Cancer Research
Monday 9 December 2024 (3 months ago) • GlobeNewswire Inc.

More Atossa Therapeutics Inc News Articles

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions